CSL's Other Operating Expense for the
six
months ended in Dec. 2025 was MXN8,877 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was MXN8,877 Mil.
CSL's quarterly Other Operating Expense
declined
from Jun. 2024 (MXN9,325 Mil) to Jun. 2025 (MXN0 Mil) but then
increased
from Jun. 2025 (MXN0 Mil) to Dec. 2025 (MXN8,877 Mil).
CSL's annual Other Operating Expense
increased
from Jun. 2023 (MXN14,247 Mil) to Jun. 2024 (MXN17,184 Mil) and
increased
from Jun. 2024 (MXN17,184 Mil) to Jun. 2025 (MXN19,149 Mil).
CSL Other Operating Expense Related Terms
CSL Other Operating Expense Historical Data
* Premium members only.
The historical data trend for CSL's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was MXN8,877 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of MXN8,877 Mil mean?
CSL (MEX:CSL N) has a Other Operating Expense of MXN8,877 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on CSL and its competitors.
Is CSL's Other Operating Expense too high?
CSL's current Other Operating Expense is MXN8,877 Mil. Overall, CSL has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does CSL's Other Operating Expense compare to VRTX and REGN?
CSL's Other Operating Expense of MXN8,877 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on CSL and its competitors. CSL's current Other Operating Expense is MXN8,877 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
CSL (MEX:CSL N) has a current Other Operating Expense of MXN8,877 Mil. The stock's GF Value™ is MXN4,856.14, compared to a current price of MXN2,081.30 — trading 57.1% below its estimated fair value. The current Other Operating Expense is MXN8,877 Mil. CSL's overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For CSL (MEX:CSL N), the current Other Operating Expense is MXN8,877 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (MEX:CSL N) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of MXN2,081.30 is trading 57.1% below its estimated GF Value™ of MXN4,856.14.
Key valuation signals for MEX:CSL N:
Other Operating Expense: MXN8,877 Mil
GF Value™: MXN4,856.14 vs. price of MXN2,081.30 (57.1% below fair value)
No single metric tells the full story. See the MEX:CSL N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
79GF Score
Get the complete analysis for MEX:CSL N
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:CSL N has been successfully added to your 
